|Table of Contents|

Relationship between UGT1A1 * 28 gene polymorphism and irinotecan-induced toxicity and response to chemotherapy

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2019 06
Page:
1087-1089
Research Field:
Publishing date:

Info

Title:
Relationship between UGT1A1 * 28 gene polymorphism and irinotecan-induced toxicity and response to chemotherapy
Author(s):
Cao Jian
Department of Hematology and Oncology，The People's Hospital of Linqu，Shandong Linqu 262600，China.
Keywords:
UGT; irinotecan; polymorphism; toxicity
PACS:
R730.53
DOI:
10.3969/j.issn.1672-4992.2019.06.045
Abstract:
Irinotecan limiting its widespread use in the treatment of various malignancies because of severe myelosuppression and delayed diarrhea.Irinotecan metabolism is regulated by a variety of genes,which uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) plays a key role.This article describes the mechanism of irinotecan-induced toxicity,the response to chemotherapy and the relationship with UGT1A1*28 polymorphism,and provides a new perspective for the individualized treatment of cancer.

References:

［1］Siegel RL,Miller KD,Jemal A.Cancer statistics,2019［J］.CA Cancer J Clin，2019,69(1):7-34.
［2］ Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015［J］.CA:A Cancer Journal for Clinicians,2016,66(2):115-132.
［3］ Xu Q,Ding YY,Song LX,et al.Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer［J］.Genet Mol Res,2015,14(2):7241-7247.
［4］ Li J,Yu Q,Fu S,et al.A novel genetic score model of UGT1A1 and TGFB pathway as predictor of severe irinotecan-related diarrhea in metastatic colorectal cancer patients［J］.Journal of Cancer Research and Clinical Oncology,2016,142(7):1621-1628.
［5］ Wang W,Huang J,Tao Y,et al.Phase II and UGT1A1 polymorphism study of two different irinotecan dosages combined with cisplatin as first-line therapy for advanced gastric cancer［J］.Chemotherapy,2016,61(4):197-203.
［6］ McKenzie JA,Mbofung RM,Malu S,et al.The effect of topoisomerase I inhibitors on the efficacy of T-cell-based cancer immunotherapy［J］.J Natl Cancer Inst,2018,110(7):1-10.
［7］ Delgado JL,Hsieh CM,Chan NL.Topoisomerases as anticancer targets［J］.Biochem J,2018,475(2):373-398.
［8］Campbell JM,Stephenson MD,Bateman E,et al.Irinotecan-induced toxicity pharmacogenetics:An umbrella review of systematic reviews and meta-analyses［J］.Pharmacogenomics J,2017,17(1):21-28.
［9］Yoshino K,Kamiura S,Yokoi T,et al.Combination chemotherapy with irinotecan and gemcitabine for taxane/platinum-resistant/refractory ovarian and primary peritoneal cancer:A multicenter phase I/II trial (GOGO-OV6)［J］.Cancer Chemother Pharmacol,2017,80(6):1239-1247.
［10］Phelip JM,Mineur L,De la Fouchardière C,et al.High resectability rate of initially unresectable colorectal liver metastases after UGT1A1-adapted high-dose irinotecan combined with LV5FU2 and cetuximab:A multicenter phase II study (ERBIFORT) ［J］.Ann Surg Oncol,2016,23(7):2161-2166.
［11］ Miyamoto M,Takano M,Kuwahara M,et al.Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas:preliminary analysis and literature review［J］.Cancer Chemother Pharmacol,2018,81(1):111-117.
［12］ Wang H,Wu XN,Ding L,et al.Relationship between irinotecan related adverse reactions and UGT1A1 gene polymorphism［J］.Modern Oncology，2013，21（1）：161-163.［王晖,武晓楠,丁丽,等.伊立替康相关不良反应与UGT1A1基因多态性的关系［J］．现代肿瘤医学，2013，21(1)：161-163．］
［13］ Ogawara D,Fukuda M,Nakamura Y,et al.Life-threatening toxicity in a patient with UGT1A1 * 6 heterozygous polymorphism after irinotecan-based chemotherapy：a case report［J］.Acta Med Nagasaki,2015,59(2):63-65.
［14］ Irose K,Kozu C,Yamashita K,et al．Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild type UGT1A1 gene［J］．Oncol Lett，2012，3(3)：694-698．
［15］ Teh LK,Hashim H,Zakaria ZA,et al.Polymorp hisms of UGT1A1*6 UGT1A1*27&UGT1A1*28 in three major ethnic groups from Malaysia［J］．Indian J Med Res,2012,136(2)：249-259．
［16］Atasilp C,Chansriwong P,Sirachainan E,et al．Correlation of UGT1A1(*)28 and (*)6 polymorphisms with irinotecan-induced neutropenia in Thai colorectal cancer patients［J］.Drug Metab Pharmacokinet,2016,31(1):90-94.
［17］Liu CY,Chen PM,Chiou TJ,et al.UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affectingtreatment outcome and survival in patients with metastatic colorectal carcinoma［J］.Cancer,2008,112(9):1932-1940.
［18］ Liu D,Li J,Gao J.Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy:a retrospective analysis［J］.BMC Cancer,2017,17(1):437.
［19］ Liu Xing-Han,Lu Jun.Predictive value of UGT1A1*28 polymorphism in irinotecan-based chemotherapy［J］.Journal of Cancer,2017,8(4):691-703.
［20］ Hu ZY,Yu Q,Zhao YS.Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea:a meta-analysis［J］.Eur J Cancer,2010,46(10):1856-1865.
［21］ H Peng,Z Duan,D Pan,et al.UGT1A1 gene polymorphism predicts irinotecan-induced severe neutropenia and diarrhea in Chinese cancer patients［J］.Clin Lab,2017,63(9):1339-1346.
［22］ Chen YJ,Hu F,Li CY,et al.The association of UGT1A1*6 and UGT1A1*28 with irinotecan-induced neutropenia in Asians:a meta-analysis［J］.Biomarkers,2014,19(1):56-62.
［23］ Sunakawa Y,Ichikawa W,Fujita K.UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer［J］.Cancer Chemother Pharmacol,2011,68(2):279-284.
［24］ Chen X,Liu L,Guo Z,et al.UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with lung cancer:a meta-analysis［J］.Cancer Chemother Pharmacol,2017,79(6):1109-1117.
［25］ Yan L,Wang XF,Wei LM.Effects of UGT1A1*6,UGT1A1*28,and ABCB1-3435C>T polymorphisms on irinotecan induced toxicity in Chinese cancer patients［J］.Int J Clin Pharmacol Ther,2016,54(3):193-199.
［26］ Yoshihama T,Hirasawa A,Nomura H,et al.UGT1A1 polymorphism as a prognostic indicator of stage I ovarian clear cell carcinoma patients treated with irinotecan［J］.Jpn J Clin Oncol,2017,47(2):170-174.
［27］ Emami AH,Sadighi S,Shirkoohi R,et al.Prediction of response to irinotecan and drug toxicity based on pharmacogenomics test:A prospective case study in advanced colorectal cancer［J］.Asian Pac J Cancer Prev,2017,18(10):2803-2807.
［28］ Takano M,Sugiyama.TUGT1A1 polymorphisms in cancer:impact on irinotecan treatment［J］.Pharmgenomics Pers Med,2017,10:61-68.
［29］Xu C,Tang X,Qu Y,et al.UGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancer［J］.Cancer Chemother Pharmacol,2016,78(1):119-130.
［30］ Dias MM,Pignon JP,Karapetis CS,et al.The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy:a collaborative meta-analysis［J］.The Pharmacogenomics Journal,2014,14(5):424-431.
［31］ Zulus B,Grünbacher G,Kleber ME,et al.The UGT1A1*28 gene variant predicts long-term mortality in patients undergoing coronary angiography［J］.Clinical Chemistry and Laboratory Medicine,(2017-12-07)［2018-02-12］.https://www.degruyter.com/downloadpdf/j/cclm.ahead-of-print/cclm-2017-0692/cclm-2017-0692.

Memo

Memo:
-
Last Update: 1900-01-01